Exelixis (EXEL) announced that its partner Ipsen (IPSEY) received a positive opinion from the European Medicine Agency’s Committee for Medicinal Products for Human Use for CABOMETYX for adult patients with unresectable or metastatic, well-differentiated extra-pancreatic and pancreatic neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. The European Commission, which has the authority to approve medicines for the European Union, will now review the CHMP recommendation, and a final decision on the application is expected in the coming months.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis
- Exelixis price target raised to $47 from $40 at H.C. Wainwright
- Exelixis price target raised to $46 from $45 at BofA
- Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
- Exelixis Holds Annual Meeting, Elects New Directors